Novartis today announced that it has entered into an agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts focused on developing novel radioligand therapies (RLTs) to treat cancers with high unmet patient need.

诺华今天宣布，它已签署协议，收购Mariana Oncology，这是一家位于马萨诸塞州沃特敦的临床前阶段生物技术公司，专注于开发新型放射性配体疗法（RLT），以治疗未满足患者需求的癌症。

The transaction bolsters the Novartis RLT pipeline and expands the company’s research infrastructure and clinical supply capabilities, supporting Novartis strategic priorities in oncology and RLT platform innovation. The acquisition encompasses a robust portfolio of RLT programs spanning lead optimization to early development across a range of solid tumor indications such as breast, prostate and lung cancer – including development candidate MC-339, an actinium-based RLT being investigated in small cell lung cancer.

该交易加强了诺华RLT管道，扩大了公司的研究基础设施和临床供应能力，支持了诺华在肿瘤学和RLT平台创新方面的战略重点。此次收购涵盖了一系列强大的RLT项目组合，涵盖了乳腺癌、前列腺癌和肺癌等一系列实体瘤适应症的铅优化和早期开发，包括开发候选药物MC-339，一种正在小细胞肺癌中研究的基于锕的RLT。

“The acquisition of Mariana Oncology reflects our commitment to radioligand therapy as one of our company’s key technology platforms and strengthens our leadership in this field,” said Fiona Marshall, President of Biomedical Research at Novartis. “We are excited to work with the Mariana team to bring forward next-generation RLTs for patients living with cancer and together shape the future of RLT as a pillar for oncology treatment.” RLTs, or radiopharmaceuticals, are a form of precision medicine that combines a tumor-targeting molecule (ligand) with a therapeutic radioisotope (a radioactive particle)..

诺华生物医学研究总裁菲奥娜·马歇尔（FionaMarshall）表示：“收购马里亚纳肿瘤学（Mariana Oncology）反映了我们对放射性配体治疗作为公司关键技术平台之一的承诺，并加强了我们在该领域的领导地位。”。“我们很高兴与马里亚纳团队合作，为癌症患者推出下一代RLT，并共同塑造RLT作为肿瘤治疗支柱的未来。”RLT或放射性药物是一种精密医学，将肿瘤靶向分子（配体）与治疗性放射性同位素（放射性粒子）结合起来。